Coronavirus Studies in Nonhuman Primate Models
This page provides a curated list of coronavirus studies and reviews using nonhuman primate (NHP) models.
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Perelman School of Medicine; University of Wisconsin-Madison; The Children's Hospital of Philadelphia; Cardiomyogen; ORRA Group, LLC; Stanford University, and others
Keywords: SARS-CoV-2, AAV vectors, immunization, immune response, mice, primates
Summary of Study: These studies demonstrate not only that AAV6 and AAV9 can function as effective vaccine platforms, but also that vaccine can provide long-term efficacy primarily through the induction of cellular immunity.
References: doi: 10.1101/2021.08.16.456441
Contact Info: Hansell Stedman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.08.16.456441v1.article-metrics
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Perelman School of Medicine; University of Wisconsin-Madison; The Children's Hospital of Philadelphia; Cardiomyogen; ORRA Group, LLC; Stanford University, and others
Keywords: SARS-CoV-2, AAV vectors, immunization, immune response, mice, primates
Summary of Study: These studies demonstrate not only that AAV6 and AAV9 can function as effective vaccine platforms, but also that vaccine can provide long-term efficacy primarily through the induction of cellular immunity.
References: doi: 10.1101/2021.08.16.456441
Contact Info: Hansell Stedman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.08.16.456441v1.article-metrics
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Yerkes National Primate Research Center; University of Pittsburgh; Emory University School of Medicine
Keywords: SARS-CoV-2, macrophages, inflammation, mRNA analysis, kinase inhibitor, primates
Summary of Study: Multi-omic analyses of hyperacute SARS-CoV-2 infection in rhesus macaques identified two populations of infiltrating macrophages as the primary orchestrators of inflammation in the lower airway that can be successfully treated with baricitinib.
References: doi: 10.1101/2021.10.05.463212
Contact Info: Steven Bosinger: [email protected]; Mirko Paiardini: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.10.05.463212v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Yerkes National Primate Research Center; University of Pittsburgh; Emory University School of Medicine
Keywords: SARS-CoV-2, macrophages, inflammation, mRNA analysis, kinase inhibitor, primates
Summary of Study: Multi-omic analyses of hyperacute SARS-CoV-2 infection in rhesus macaques identified two populations of infiltrating macrophages as the primary orchestrators of inflammation in the lower airway that can be successfully treated with baricitinib.
References: doi: 10.1101/2021.10.05.463212
Contact Info: Steven Bosinger: [email protected]; Mirko Paiardini: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.10.05.463212v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Laboratory of Virology (NIAID/NIH), Rocky Mountain Veterinary Branch (NIAID/NIH), CureVac AG
Keywords: SARS-CoV-2, mRNA vaccine candidate, humoral and cellular immune responses, primates
Summary of Study: A new SARS-CoV-2 S mRNA vaccine, CV07050101 was investigated in NHPs. Prime-boost vaccination of rhesus macaques with 4 ug of CV07050101 does not elicit a uniform nor robust immune response; however, vaccination using 8 ug of the same vaccine demonstrated protection.
References: PMID: 34268507 / doi: 10.1101/202.07.07.451505
Contact Info: Vincent Munster: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.07.451505v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Laboratory of Virology (NIAID/NIH), Rocky Mountain Veterinary Branch (NIAID/NIH), CureVac AG
Keywords: SARS-CoV-2, mRNA vaccine candidate, humoral and cellular immune responses, primates
Summary of Study: A new SARS-CoV-2 S mRNA vaccine, CV07050101 was investigated in NHPs. Prime-boost vaccination of rhesus macaques with 4 ug of CV07050101 does not elicit a uniform nor robust immune response; however, vaccination using 8 ug of the same vaccine demonstrated protection.
References: PMID: 34268507 / doi: 10.1101/202.07.07.451505
Contact Info: Vincent Munster: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.07.451505v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Scripps Research Institute; MIT; UCSD; Howard Hughes Medican Institute
Keywords: SARS-CoV-2, receptor-binding domain vaccine, structural studies, immune response, primates
Summary of Study: Broadly neutralizing antibodies to an unappreciated site of conservation in the RBD in SARS-related viruses can be readily induced in rhesus macaques because of distinct properties of the naive macaque B cell repertoire that suggest prudence in the use of the macaque model in SARS vaccine evaluation and design.
References: doi: 10.1101/2021.07.05.451222
Contact Info: Ian Wilson: [email protected]; Dennis Burton: [email protected]; Raiees Andrabi: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.05.451222v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Scripps Research Institute; MIT; UCSD; Howard Hughes Medican Institute
Keywords: SARS-CoV-2, receptor-binding domain vaccine, structural studies, immune response, primates
Summary of Study: Broadly neutralizing antibodies to an unappreciated site of conservation in the RBD in SARS-related viruses can be readily induced in rhesus macaques because of distinct properties of the naive macaque B cell repertoire that suggest prudence in the use of the macaque model in SARS vaccine evaluation and design.
References: doi: 10.1101/2021.07.05.451222
Contact Info: Ian Wilson: [email protected]; Dennis Burton: [email protected]; Raiees Andrabi: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.05.451222v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Peking University Health Science Center, Beijing, China
Keywords: SARS-CoV-2, TLR4, trimeric spike protein binding, primates
Summary of Study: The spike protein of SARS-CoV-2 functions as a potent stimulus causing TLR4 activation and sepsis related abnormal responses.
References: doi: https://doi.org/10.1101/2020.12.18.423427
Contact Info: Xiangxi Wang: [email protected]/Fuping You: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.18.423427v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Peking University Health Science Center, Beijing, China
Keywords: SARS-CoV-2, TLR4, trimeric spike protein binding, primates
Summary of Study: The spike protein of SARS-CoV-2 functions as a potent stimulus causing TLR4 activation and sepsis related abnormal responses.
References: doi: https://doi.org/10.1101/2020.12.18.423427
Contact Info: Xiangxi Wang: [email protected]/Fuping You: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.18.423427v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: ImmunityBio, Culver City, CA
Keywords: SARS-CoV-2, prime and oral boost bivalent hAd5 vaccination, T-cell response, primates
Summary of Study: Treatment with bivalent hAd5S-Fusion + N-ETSD subcutaneous and oral vaccine provided complete protection of nasal and lung airways against SARS-CoV-2 challenge in rhesus macaques. Data demonstrate that all NHPs immunized with the hAD5 S-Fusion + N-ETSD vaccine generated anti-S IgG and that 9 of 10 animals showed inhibition in cPass (TM) and thus the presence of anti-S RBD neutralizing antibodies.
References: doi: https://doi.org/10.1101/2020.12.08.416297
Contact Info: Patrick Soon-Shiong: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.08.416297v3
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: ImmunityBio, Culver City, CA
Keywords: SARS-CoV-2, prime and oral boost bivalent hAd5 vaccination, T-cell response, primates
Summary of Study: Treatment with bivalent hAd5S-Fusion + N-ETSD subcutaneous and oral vaccine provided complete protection of nasal and lung airways against SARS-CoV-2 challenge in rhesus macaques. Data demonstrate that all NHPs immunized with the hAD5 S-Fusion + N-ETSD vaccine generated anti-S IgG and that 9 of 10 animals showed inhibition in cPass (TM) and thus the presence of anti-S RBD neutralizing antibodies.
References: doi: https://doi.org/10.1101/2020.12.08.416297
Contact Info: Patrick Soon-Shiong: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.08.416297v3
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: University of Bern
Keywords: SARS-CoV-2, airway epithelial cell (AEC) culture repository, multiple animal species
Summary of Study: Well-differentiated primary airway epithelial cell cultures were established from various domestic and wildlife animal species (including rhesus macaques) to assess the potential intermediate and spillback host reservoir spectrum of SARS-CoV-2. rhesus macaque post-mortem tracheobronchial airway tissue material. These were inoculated with SARS-CoV-2/Munchen-1.1/2020/929 isolate and monitored for viral titer for 96 hours. Infectious progeny virus were absent in most species, except rhesus macaques and cats, indicating that some species are not ideally suited as animal models in studies of SARS-CoV-2.
References: doi: https://doi.org/10.1101/2020.11.10.374587
Contact Info: Ronald Dijkman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.10.374587v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: University of Bern
Keywords: SARS-CoV-2, airway epithelial cell (AEC) culture repository, multiple animal species
Summary of Study: Well-differentiated primary airway epithelial cell cultures were established from various domestic and wildlife animal species (including rhesus macaques) to assess the potential intermediate and spillback host reservoir spectrum of SARS-CoV-2. rhesus macaque post-mortem tracheobronchial airway tissue material. These were inoculated with SARS-CoV-2/Munchen-1.1/2020/929 isolate and monitored for viral titer for 96 hours. Infectious progeny virus were absent in most species, except rhesus macaques and cats, indicating that some species are not ideally suited as animal models in studies of SARS-CoV-2.
References: doi: https://doi.org/10.1101/2020.11.10.374587
Contact Info: Ronald Dijkman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.10.374587v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: pigtail macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: National Institute of Allergy and
Infectious Diseases, National Institutes of Health; Washington National Primate Research Center, University of Washington; HDT Bio; Fred Hutchinson Cancer Research Center
Keywords: SARS-CoV-2, replicon RNA vaccine, neutralizing antibody response, pathology, primates
Summary of Study: A self-amplifying replicon RNA vaccine elicits protective immunity to COVID-19 and a strong protective response even after antibody levels decreased to undetectable levels.
References: PMID: 35982677 / doi: 10.1101/2022.08.08.503239
Contact Info: Deborah Heydenburg Fuller; Jesse H. Erasmus
URL: https://www.biorxiv.org/content/10.1101/2022.08.08.503239v1
NHP Species: pigtail macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: National Institute of Allergy and
Infectious Diseases, National Institutes of Health; Washington National Primate Research Center, University of Washington; HDT Bio; Fred Hutchinson Cancer Research Center
Keywords: SARS-CoV-2, replicon RNA vaccine, neutralizing antibody response, pathology, primates
Summary of Study: A self-amplifying replicon RNA vaccine elicits protective immunity to COVID-19 and a strong protective response even after antibody levels decreased to undetectable levels.
References: PMID: 35982677 / doi: 10.1101/2022.08.08.503239
Contact Info: Deborah Heydenburg Fuller; Jesse H. Erasmus
URL: https://www.biorxiv.org/content/10.1101/2022.08.08.503239v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Ology Bioservices; Harvard Medical School; Vanderbilt University Medical Center; US Department of Defense; Logistics Management Institute; Washington University School of Medicine
Keywords: SARS-CoV-2, antibody treatment, spike protein, protection, primates
Summary of Study: Passive transfer of two neutralizing antibodies (COV2-2130 and COV2-2381) given prophylactically -- either individually or in combination (combination designated ADM03820) by intravenous or intramuscular route conferred virological protection in a NHP model of SARS-CoV-2 infection, and ADM03820 potently neutralized SARS-CoV-2 variants of concern in vitro.
References: doi: 10.1101/2021.09.27.462074
Contact Info: Dan Barouch: [email protected]; James Crowe: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.27.462074v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Ology Bioservices; Harvard Medical School; Vanderbilt University Medical Center; US Department of Defense; Logistics Management Institute; Washington University School of Medicine
Keywords: SARS-CoV-2, antibody treatment, spike protein, protection, primates
Summary of Study: Passive transfer of two neutralizing antibodies (COV2-2130 and COV2-2381) given prophylactically -- either individually or in combination (combination designated ADM03820) by intravenous or intramuscular route conferred virological protection in a NHP model of SARS-CoV-2 infection, and ADM03820 potently neutralized SARS-CoV-2 variants of concern in vitro.
References: doi: 10.1101/2021.09.27.462074
Contact Info: Dan Barouch: [email protected]; James Crowe: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.27.462074v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Jiangsu Rec-biotechnology Co Ltd, China; Chinese Academy of Medical Sciences; Wuhan University; Jiangsu Provincial Center for Disease Control and Prevention
Keywords: SARS-CoV-2, subunit vaccine, protective immunity, mice, primates
Summary of Study: Two-dose immunizations of ReCOV, a recombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine adjuvanted with BFA03, provided complete protection against challenge with SARS-CoV-2 in hACE2 transgenic mice and rhesus macaques, without observable antibody-dependent enhancement of infection.
References: doi: 10.1101/2021.11.03.467182
Contact Info: Yong Liu: [email protected]; Feng-Cai Zhu: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.11.03.467182v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Jiangsu Rec-biotechnology Co Ltd, China; Chinese Academy of Medical Sciences; Wuhan University; Jiangsu Provincial Center for Disease Control and Prevention
Keywords: SARS-CoV-2, subunit vaccine, protective immunity, mice, primates
Summary of Study: Two-dose immunizations of ReCOV, a recombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine adjuvanted with BFA03, provided complete protection against challenge with SARS-CoV-2 in hACE2 transgenic mice and rhesus macaques, without observable antibody-dependent enhancement of infection.
References: doi: 10.1101/2021.11.03.467182
Contact Info: Yong Liu: [email protected]; Feng-Cai Zhu: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.11.03.467182v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Tulane National Primate Research Center, Northwestern University, Duke University Medical Center, Tulane School of Medicine
Keywords: SARS-CoV-2, monoclonal antibodies, neutralization, mucosal viral challenge, immune response, primates
Summary of Study: A combination of two mAbs demonstrated that administration of these mAbs at a range of doses achieved near-complete protection from viral replication and disease even when challenge occurred 75 days after mAb administration.
References: doi: 10.1101/2021.05.26.445878
Contact Info: Chad Roy: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.05.26.445878v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Tulane National Primate Research Center, Northwestern University, Duke University Medical Center, Tulane School of Medicine
Keywords: SARS-CoV-2, monoclonal antibodies, neutralization, mucosal viral challenge, immune response, primates
Summary of Study: A combination of two mAbs demonstrated that administration of these mAbs at a range of doses achieved near-complete protection from viral replication and disease even when challenge occurred 75 days after mAb administration.
References: doi: 10.1101/2021.05.26.445878
Contact Info: Chad Roy: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.05.26.445878v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Walter Reed Army Institute of Research; Washington Univ., Texas Biomedical Research Institute, and others
Keywords: SARS-CoV-2, spike ferritin nanoparticle vaccine, immune response, pathology, primates
Summary of Study: A SARS-CoV-2 spike protein ferritin nanoparticle vaccine, co-formulated with a liposomal adjuvant, elicits broad neutralizing antibody responses that exceed those observed for other major vaccines and rapidly protects against respiratory infection and disease in the upper and lower airways and lung tissue of NHPs.
References: PMID: 33791694 / doi: 10.1101/2021.03.24.436523
Contact Info: Kayvon Modjarrad: [email protected]; Michael Joyce: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.03.24.436523v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Walter Reed Army Institute of Research; Washington Univ., Texas Biomedical Research Institute, and others
Keywords: SARS-CoV-2, spike ferritin nanoparticle vaccine, immune response, pathology, primates
Summary of Study: A SARS-CoV-2 spike protein ferritin nanoparticle vaccine, co-formulated with a liposomal adjuvant, elicits broad neutralizing antibody responses that exceed those observed for other major vaccines and rapidly protects against respiratory infection and disease in the upper and lower airways and lung tissue of NHPs.
References: PMID: 33791694 / doi: 10.1101/2021.03.24.436523
Contact Info: Kayvon Modjarrad: [email protected]; Michael Joyce: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.03.24.436523v1
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Tokyo, Daichi Sankyo Col, Shiga University of Medical science, and others
Keywords: SARS-CoV-2, lipid nanoparticle-based mRNA vaccine candidate, immunogenicity, primates
Summary of Study: Macaques administered with LNP-mRNA targeting RBD acquired significantly high levels of protective IgG specific to SARS-CoV-2 in mucosal swab samples from conjunctiva, oral cavity, nasal cavity, trachea, bronchus, and rectum.
References: doi: 10.1101/2021.03.04.433852
Contact Info: Ken Ishii: [email protected]; Yoshihiro Kawaoka: [email protected]; Fumihiko Takeshita: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.03.04.433852v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Tokyo, Daichi Sankyo Col, Shiga University of Medical science, and others
Keywords: SARS-CoV-2, lipid nanoparticle-based mRNA vaccine candidate, immunogenicity, primates
Summary of Study: Macaques administered with LNP-mRNA targeting RBD acquired significantly high levels of protective IgG specific to SARS-CoV-2 in mucosal swab samples from conjunctiva, oral cavity, nasal cavity, trachea, bronchus, and rectum.
References: doi: 10.1101/2021.03.04.433852
Contact Info: Ken Ishii: [email protected]; Yoshihiro Kawaoka: [email protected]; Fumihiko Takeshita: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.03.04.433852v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Rocky Mountain Laboratories/NIAID/NIH, University of Colorado School of Medicine
Keywords: SARS-CoV-2, T cells, immune response, pathology, primates
Summary of Study: T-cells play a role in the recovery of rhesus macaques from acute SARS-CoV-2 infections, although their depletion does not induce severe disease, and T cells do not account for the natural resistance of rhesus macaques to severed COVID-19. Neither primed CD4+ or CD8+ T cells appeared critical for immunoglobulin class switching, the development of immunological memory or protection from a second infection.
References: PMID: 33821272 / doi: 10.1101/2021.04.02.438262
Contact Info: Kim Hasenkrug: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.04.02.438262v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Rocky Mountain Laboratories/NIAID/NIH, University of Colorado School of Medicine
Keywords: SARS-CoV-2, T cells, immune response, pathology, primates
Summary of Study: T-cells play a role in the recovery of rhesus macaques from acute SARS-CoV-2 infections, although their depletion does not induce severe disease, and T cells do not account for the natural resistance of rhesus macaques to severed COVID-19. Neither primed CD4+ or CD8+ T cells appeared critical for immunoglobulin class switching, the development of immunological memory or protection from a second infection.
References: PMID: 33821272 / doi: 10.1101/2021.04.02.438262
Contact Info: Kim Hasenkrug: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.04.02.438262v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques, pigtail macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Washington, UNC, Chapel Hill and others
Keywords: SARS-CoV-2, multivalent receptor-binding domain nanoparticle vaccine, immune response, variants, mice and primates
Summary of Study: Mosaic and cocktail sarbecovirus RBD-NPs elicit broad and protective Ab responses against heterologous sarbecovirus challenge, which could represent the next generation of pan-sarbecovirus vaccines.
References: PMID: 33758839 / doi: 10.1101/2021.03.15.435528
Contact Info: Neil King: [email protected]; David Veesler: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.03.15.435528v1
NHP Species: rhesus macaques, pigtail macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Washington, UNC, Chapel Hill and others
Keywords: SARS-CoV-2, multivalent receptor-binding domain nanoparticle vaccine, immune response, variants, mice and primates
Summary of Study: Mosaic and cocktail sarbecovirus RBD-NPs elicit broad and protective Ab responses against heterologous sarbecovirus challenge, which could represent the next generation of pan-sarbecovirus vaccines.
References: PMID: 33758839 / doi: 10.1101/2021.03.15.435528
Contact Info: Neil King: [email protected]; David Veesler: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.03.15.435528v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Janssen Vaccines and Prevention, The Netherlands
Keywords: SARS-CoV-2, adenovirus-vectored vaccine, neutralization potency, aged animals, primates
Summary of Study: The Janssen Ad26.COV2.S vaccine candidate is currently the only one evaluated as a single dose vaccination regimen in Phase 3 clinical studies. This study showed that a second vaccine dose (administered 8 weeks post the first immunization) induced a significant increase in antigen-specific binding and neutralizing antibody responses in both adult and aged rhesus macaques as compared to a single dose. These data support the initiation of a two-dose Ad26.COV2.S regimen in Phase 3 clinical trial in adults and elderly.
References: doi: https://doi.org/10.1101/2020.11.17.368258
Contact Info: Roland Zahn: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.17.368258v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Janssen Vaccines and Prevention, The Netherlands
Keywords: SARS-CoV-2, adenovirus-vectored vaccine, neutralization potency, aged animals, primates
Summary of Study: The Janssen Ad26.COV2.S vaccine candidate is currently the only one evaluated as a single dose vaccination regimen in Phase 3 clinical studies. This study showed that a second vaccine dose (administered 8 weeks post the first immunization) induced a significant increase in antigen-specific binding and neutralizing antibody responses in both adult and aged rhesus macaques as compared to a single dose. These data support the initiation of a two-dose Ad26.COV2.S regimen in Phase 3 clinical trial in adults and elderly.
References: doi: https://doi.org/10.1101/2020.11.17.368258
Contact Info: Roland Zahn: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.17.368258v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: african green monkeys
Year Published:
Study Type/Review: vaccine
NPRC/Institute: City of Hope National Medical Center; Bioqual
Keywords: SARS-CoV-2, vaccine efficacy, humoral and cellular immune responses, primates
Summary of Study: COH04S1, a synthetic multiantigen Modified Vaccinia Ankara-based SARS-CoV-2 vaccine that co-expresses spike and nucleocapsid antigens, demonstrated protection in animal models through different vaccination routes and dose regimens, complementing ongoing investigation of this multiantigen SARS-CoV-2 vaccine in clinical trials.
References: PMID: 34545366 / doi: 10.1101/2021.09.15.460487
Contact Info: Felix Wussow: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.15.460487v1
NHP Species: african green monkeys
Year Published:
Study Type/Review: vaccine
NPRC/Institute: City of Hope National Medical Center; Bioqual
Keywords: SARS-CoV-2, vaccine efficacy, humoral and cellular immune responses, primates
Summary of Study: COH04S1, a synthetic multiantigen Modified Vaccinia Ankara-based SARS-CoV-2 vaccine that co-expresses spike and nucleocapsid antigens, demonstrated protection in animal models through different vaccination routes and dose regimens, complementing ongoing investigation of this multiantigen SARS-CoV-2 vaccine in clinical trials.
References: PMID: 34545366 / doi: 10.1101/2021.09.15.460487
Contact Info: Felix Wussow: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.15.460487v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Ragon Institute of MGH, MIT and Harvard
Keywords: SARS-CoV-2, humoral immune response, recombinant full-length spike glycoprotein (NVX-CoV2373), primates
Summary of Study: Deep profiling of the humoral immune response in a cohort of non-human primates immunized with one or two doses of 5 or 25 ug of a stabilized recombinant full-length SARS-CoV-2 spike glycoprotein with 50 ug Matrix-M adjuvant suggests that a single dose of may prevent disease, but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.
References: PMID: 33619473 / doi: 10.21203/rs.3.rs-200342/v1
Contact Info: Galit Alter: [email protected]
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899467/pdf/nihpp-rs200342v1.pdf
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Ragon Institute of MGH, MIT and Harvard
Keywords: SARS-CoV-2, humoral immune response, recombinant full-length spike glycoprotein (NVX-CoV2373), primates
Summary of Study: Deep profiling of the humoral immune response in a cohort of non-human primates immunized with one or two doses of 5 or 25 ug of a stabilized recombinant full-length SARS-CoV-2 spike glycoprotein with 50 ug Matrix-M adjuvant suggests that a single dose of may prevent disease, but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.
References: PMID: 33619473 / doi: 10.21203/rs.3.rs-200342/v1
Contact Info: Galit Alter: [email protected]
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899467/pdf/nihpp-rs200342v1.pdf
Coronavirus Investigated: SARS-CoV-2
NHP Species: african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: University of TX Medical Branch
Keywords: SARS-CoV-2, convalescent sera, primates, viral load and disease pathology
Summary of Study: Groups of SARS-CoV-2 infected AGMs were treated with pooled convalescent sera containing either high or low to moderate anti-SARS-CoV-2 neutralizing antibody titers. Lower levels of SARS-CoV-2 in respiratory compartments, reduced gross and histopathological lesion severity in the lungs, and reductions in several parameters associated with coagulation and inflammatory processes were observed in monkeys that received convalescent sera versus untreated controls.
References: doi: https://doi.org/10.1101/2020.10.14.340091
Contact Info: Thomas Geisbert: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.10.14.340091v1
NHP Species: african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: University of TX Medical Branch
Keywords: SARS-CoV-2, convalescent sera, primates, viral load and disease pathology
Summary of Study: Groups of SARS-CoV-2 infected AGMs were treated with pooled convalescent sera containing either high or low to moderate anti-SARS-CoV-2 neutralizing antibody titers. Lower levels of SARS-CoV-2 in respiratory compartments, reduced gross and histopathological lesion severity in the lungs, and reductions in several parameters associated with coagulation and inflammatory processes were observed in monkeys that received convalescent sera versus untreated controls.
References: doi: https://doi.org/10.1101/2020.10.14.340091
Contact Info: Thomas Geisbert: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.10.14.340091v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Harvard Medical School
Keywords: SARS-CoV-2, AAV-based, single dose vaccine, primates
Summary of Study: Two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and NHP models following a single injection. Moreover, the vaccine is stable at room temperature for a least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry.
References: doi: https://doi.org/10.1101/2021.01.05.422952
Contact Info: Luk Vandenberghe: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.01.05.422952v3
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Harvard Medical School
Keywords: SARS-CoV-2, AAV-based, single dose vaccine, primates
Summary of Study: Two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and NHP models following a single injection. Moreover, the vaccine is stable at room temperature for a least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry.
References: doi: https://doi.org/10.1101/2021.01.05.422952
Contact Info: Luk Vandenberghe: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.01.05.422952v3
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: CNPRC/Vitalant
Keywords: SARS-CoV-2, protective immunity, CD4 helper cells, primates
Summary of Study: vaccine promoting Th1-type Tfh responses that target the S protein may lead to protective immunity
References: doi: 10.1101/2020.07.07.191007
Contact Info: Sonny Elizaldi, UC Davis CIID
URL: https://www.biorxiv.org/content/10.1101/2020.07.07.191007v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: CNPRC/Vitalant
Keywords: SARS-CoV-2, protective immunity, CD4 helper cells, primates
Summary of Study: vaccine promoting Th1-type Tfh responses that target the S protein may lead to protective immunity
References: doi: 10.1101/2020.07.07.191007
Contact Info: Sonny Elizaldi, UC Davis CIID
URL: https://www.biorxiv.org/content/10.1101/2020.07.07.191007v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: marmosets
Year Published:
Study Type/Review:
NPRC/Institute: Tsinghua University; Chongqing Medical University; Chinese Academy of Sciences; Shenzhen Bay Laboratory; Peking University Shenzhen Graduate School, Fudan University
Keywords: SARS-CoV-2, virus variants, entry efficiency, host tropism, sensitivity to neutralizing antibodies, primates
Summary of Study: Results demonstrated that the spike protein of Kappa, Delta or B.1.618 with distinct mutations have altered their ability in utilizing ACE2 orthologs for cell entry.
References: doi: 10.1101/2021.09.03.458829
Contact Info: Qiang Ding: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.03.458829v1
NHP Species: marmosets
Year Published:
Study Type/Review:
NPRC/Institute: Tsinghua University; Chongqing Medical University; Chinese Academy of Sciences; Shenzhen Bay Laboratory; Peking University Shenzhen Graduate School, Fudan University
Keywords: SARS-CoV-2, virus variants, entry efficiency, host tropism, sensitivity to neutralizing antibodies, primates
Summary of Study: Results demonstrated that the spike protein of Kappa, Delta or B.1.618 with distinct mutations have altered their ability in utilizing ACE2 orthologs for cell entry.
References: doi: 10.1101/2021.09.03.458829
Contact Info: Qiang Ding: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.03.458829v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques, african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: Tulane National Primate Research Center; Tulane University School of Medicine; Zalgen Labs, LLC., Duke University Medical Center
Keywords: SARS-CoV-2, route of experimental infection, immune response, pathology, primates
Summary of Study: Lack of regenerative activity in the lung was present in both species post-resolution of most of the viral RNA, indicating the NHP model of SARS-CoV-2 infection can be utilized during anti-fibrosis therapeutic development and evaluation and has potential utility in evaluation of post-acute COVID sequelae.
References: doi: 10.1101/2021.11.28.470250
Contact Info: Chad Roy: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.11.28.470250v1
NHP Species: rhesus macaques, african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: Tulane National Primate Research Center; Tulane University School of Medicine; Zalgen Labs, LLC., Duke University Medical Center
Keywords: SARS-CoV-2, route of experimental infection, immune response, pathology, primates
Summary of Study: Lack of regenerative activity in the lung was present in both species post-resolution of most of the viral RNA, indicating the NHP model of SARS-CoV-2 infection can be utilized during anti-fibrosis therapeutic development and evaluation and has potential utility in evaluation of post-acute COVID sequelae.
References: doi: 10.1101/2021.11.28.470250
Contact Info: Chad Roy: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.11.28.470250v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: Laboratory of Virology; NIAID/NIH; University of Plymouth; The Vaccine Group, Ltd.
Keywords: SARS-CoV-2, intranasal infection, genome variants, immune response, primates
Summary of Study: UK B.1.1.7 infection of African green monkeys exhibits increased respiratory replication and shedding but no disease enhancement.
References: PMID: 34159332 / doi: 10.1101/2021.06.11.448134
Contact Info: Heinz Feldmann: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.11.448134v1
NHP Species: african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: Laboratory of Virology; NIAID/NIH; University of Plymouth; The Vaccine Group, Ltd.
Keywords: SARS-CoV-2, intranasal infection, genome variants, immune response, primates
Summary of Study: UK B.1.1.7 infection of African green monkeys exhibits increased respiratory replication and shedding but no disease enhancement.
References: PMID: 34159332 / doi: 10.1101/2021.06.11.448134
Contact Info: Heinz Feldmann: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.11.448134v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: lemurs, lorises
Year Published:
Study Type/Review:
NPRC/Institute: Univ. of Calgary, Institut de Biologia Evolutiva, New York Univ., and others
Keywords: SARS-CoV-2, ACE2 gene and protein sequences, several species, primates
Summary of Study: Susceptibility to SARS-CoV-2 is not equal across non-human primates. This study suggests that several clades of lemurs have a high potential susceptibility to SARS-CoV-2 infection. As they are among the primates at highest risk of extinction globally, further understanding of their risk should be a conservation priority. All feasible actions should be taken to limit their exposure to SARS-CoV-2.
References: PMID: 33564767 / doi: 10.1101/2021.02.03.429540
Contact Info: James Higham: [email protected]; Amanda Melin: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.03.429540v1
NHP Species: lemurs, lorises
Year Published:
Study Type/Review:
NPRC/Institute: Univ. of Calgary, Institut de Biologia Evolutiva, New York Univ., and others
Keywords: SARS-CoV-2, ACE2 gene and protein sequences, several species, primates
Summary of Study: Susceptibility to SARS-CoV-2 is not equal across non-human primates. This study suggests that several clades of lemurs have a high potential susceptibility to SARS-CoV-2 infection. As they are among the primates at highest risk of extinction globally, further understanding of their risk should be a conservation priority. All feasible actions should be taken to limit their exposure to SARS-CoV-2.
References: PMID: 33564767 / doi: 10.1101/2021.02.03.429540
Contact Info: James Higham: [email protected]; Amanda Melin: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.03.429540v1
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: State Key Laboratory of Pathogen and Biosecurity, Beijing, China
Keywords: SARS-CoV-2, recombinant subunit vaccine, neutralization potency, aged animals, primates
Summary of Study: Authors developed a pilot scale pipeline producing a recombinant subunit vaccine (RBD-Fc Vacc) with Receptor Binding Domain of SARS-CoV-2S protein fused with the Fc domain of human IgG1. This vaccine induced SARS-CoV-2 specific neutralizing antibodies in non-human primates and human ACE2 transgenic mice and is currently being assessed in randomized controlled phase I/II human clinical trials.
References: doi: https://doi.org/10.1101/2020.11.29.402339
Contact Info: Yuwei Gao: [email protected]; Wenjin Wei: [email protected]; Zhonghu Hu: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.29.402339v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: State Key Laboratory of Pathogen and Biosecurity, Beijing, China
Keywords: SARS-CoV-2, recombinant subunit vaccine, neutralization potency, aged animals, primates
Summary of Study: Authors developed a pilot scale pipeline producing a recombinant subunit vaccine (RBD-Fc Vacc) with Receptor Binding Domain of SARS-CoV-2S protein fused with the Fc domain of human IgG1. This vaccine induced SARS-CoV-2 specific neutralizing antibodies in non-human primates and human ACE2 transgenic mice and is currently being assessed in randomized controlled phase I/II human clinical trials.
References: doi: https://doi.org/10.1101/2020.11.29.402339
Contact Info: Yuwei Gao: [email protected]; Wenjin Wei: [email protected]; Zhonghu Hu: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.29.402339v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Clover Biopharmaceuticals, Chengdu, China
Keywords: SARS-CoV-2, Trimer-Tag technology, neutralizing antibodies, primates
Summary of Study: Rhesus macaques immunized with adjuvanted S-Trimer were protected from SARS-CoV-2 challenge compared to vehicle controls. Trimer-Tag may be an important new platform technology for scalable production and rapid development of safe and effective subunit vaccines against current and future emerging RNA viruses.
References: doi: https://doi.org/10.1101/2020.09.24.311027
Contact Info: Pen Liang: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.09.24.311027v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Clover Biopharmaceuticals, Chengdu, China
Keywords: SARS-CoV-2, Trimer-Tag technology, neutralizing antibodies, primates
Summary of Study: Rhesus macaques immunized with adjuvanted S-Trimer were protected from SARS-CoV-2 challenge compared to vehicle controls. Trimer-Tag may be an important new platform technology for scalable production and rapid development of safe and effective subunit vaccines against current and future emerging RNA viruses.
References: doi: https://doi.org/10.1101/2020.09.24.311027
Contact Info: Pen Liang: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.09.24.311027v1
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke University, NIAID, 3 M Company
Keywords: SARS-CoV-2, receptor binding domain nanoparticle, vaccination, immune response, primates
Summary of Study: An RBD-scNP vaccine induced robust protective immunity for SARS-CoV-2 replication in the upper and lower respiratory tract. This vaccine represents a platform for producing a pancoronavirus vaccine that could prevent, rapidly temper, or extinguish the next spillover of a coronavirus into humans.
References: doi: 10.1101/2021.02.17.431492
Contact Info: Kevin Saunders: [email protected]; Barton Haynes: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.17.431492v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke University, NIAID, 3 M Company
Keywords: SARS-CoV-2, receptor binding domain nanoparticle, vaccination, immune response, primates
Summary of Study: An RBD-scNP vaccine induced robust protective immunity for SARS-CoV-2 replication in the upper and lower respiratory tract. This vaccine represents a platform for producing a pancoronavirus vaccine that could prevent, rapidly temper, or extinguish the next spillover of a coronavirus into humans.
References: doi: 10.1101/2021.02.17.431492
Contact Info: Kevin Saunders: [email protected]; Barton Haynes: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.17.431492v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: multiple species
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke Human Vaccine Institute
Keywords: SARS-CoV-2, multimeric receptor binding domain nanoparticle, cross-neutralizing antibody, virus variants, primates
Summary of Study: This study demonstrates the ability of a SARS-CoV-2 RBD 24-mer subunit nanoparticle vaccine to elicit potent cross-neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, SARS-CoV-2 variant B.1.1.7. as well as SARS-related bat betaCoVs.
References: PMID: 33619494 / doi: 10.1101/2021.02.17.431492
Contact Info: Kevin Saunders: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.17.431492v1
NHP Species: multiple species
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke Human Vaccine Institute
Keywords: SARS-CoV-2, multimeric receptor binding domain nanoparticle, cross-neutralizing antibody, virus variants, primates
Summary of Study: This study demonstrates the ability of a SARS-CoV-2 RBD 24-mer subunit nanoparticle vaccine to elicit potent cross-neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, SARS-CoV-2 variant B.1.1.7. as well as SARS-related bat betaCoVs.
References: PMID: 33619494 / doi: 10.1101/2021.02.17.431492
Contact Info: Kevin Saunders: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.17.431492v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: NIAID, NHLBI, Emory NPRC, Bioqual, Inc.
Keywords: SARS-CoV-2, inflammation, clonal hematopoiesis, respiratory tract, primates
Summary of Study: Findings suggest potential pathophysiological differences with or without clonal hematopoiesis upon SARS-CoV-2 infection
References: doi: 10.1101/2023.01.01.522064
Contact Info: Tae-Hoon Shin: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2023.01.01.522064v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: NIAID, NHLBI, Emory NPRC, Bioqual, Inc.
Keywords: SARS-CoV-2, inflammation, clonal hematopoiesis, respiratory tract, primates
Summary of Study: Findings suggest potential pathophysiological differences with or without clonal hematopoiesis upon SARS-CoV-2 infection
References: doi: 10.1101/2023.01.01.522064
Contact Info: Tae-Hoon Shin: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2023.01.01.522064v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke University Medical Center, UNC- Chapel Hill, Louisiana State Univ., Infectious Disease Institute (Seattle, WA), Moderna, NIAID, California National Primate Research Center, Cornell Weill Medical College
Keywords: SARS-CoV-2, mRNA vaccine, nanoparticles, immune response, primates
Summary of Study: SARS-CoV-2 vaccines are well-tolerated and highly immunogenic in infant rhesus macaques.
References: PMID: 33851156 / doi: 10.1101/2021.04.05.438479
Contact Info: Kristina De Paris: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.04.05.438479v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke University Medical Center, UNC- Chapel Hill, Louisiana State Univ., Infectious Disease Institute (Seattle, WA), Moderna, NIAID, California National Primate Research Center, Cornell Weill Medical College
Keywords: SARS-CoV-2, mRNA vaccine, nanoparticles, immune response, primates
Summary of Study: SARS-CoV-2 vaccines are well-tolerated and highly immunogenic in infant rhesus macaques.
References: PMID: 33851156 / doi: 10.1101/2021.04.05.438479
Contact Info: Kristina De Paris: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.04.05.438479v1
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review:
NPRC/Institute: Nat'l Institute of Infectious Diseases, Tokyo; University of Tokyo; Kumamoto University
Keywords: SARS-CoV-2, T cells, immune response, primates
Summary of Study: Study showed that subacute SARS-CoV-2 replication can be controlled even in the absence of CD8+ T cells. In SARS-CoV-2 infection, CD8+ T-cell responses may contribute to viral control, but these results suggest that CD8+ T-cell dysfunction does not solely lead to viral control failure or disease progression.
References: doi: 10.1101/2021.05.26.445769
Contact Info: Tesuro Matano: [email protected]; Takushi Nomura: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.05.26.445769v1
NHP Species:
Year Published:
Study Type/Review:
NPRC/Institute: Nat'l Institute of Infectious Diseases, Tokyo; University of Tokyo; Kumamoto University
Keywords: SARS-CoV-2, T cells, immune response, primates
Summary of Study: Study showed that subacute SARS-CoV-2 replication can be controlled even in the absence of CD8+ T cells. In SARS-CoV-2 infection, CD8+ T-cell responses may contribute to viral control, but these results suggest that CD8+ T-cell dysfunction does not solely lead to viral control failure or disease progression.
References: doi: 10.1101/2021.05.26.445769
Contact Info: Tesuro Matano: [email protected]; Takushi Nomura: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.05.26.445769v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques, marmosets
Year Published:
Study Type/Review:
NPRC/Institute: Department of Computational Medicine and Bioinformatics, University of Michigan
Keywords: SARS-CoV-2, a computational pipeline, the binding affinity ACE2, mammals, birds, fish, reptiles, and amphibians
Summary of Study: Identifying zoonotic origin of SARS-CoV-2 by modeling the binding affinity between Spike receptor-binding domain and host ACE2
References: doi: 10.1101/2020.09.11.293449
Contact Info: Yang Zhang: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.09.11.293449v1
NHP Species: rhesus macaques, marmosets
Year Published:
Study Type/Review:
NPRC/Institute: Department of Computational Medicine and Bioinformatics, University of Michigan
Keywords: SARS-CoV-2, a computational pipeline, the binding affinity ACE2, mammals, birds, fish, reptiles, and amphibians
Summary of Study: Identifying zoonotic origin of SARS-CoV-2 by modeling the binding affinity between Spike receptor-binding domain and host ACE2
References: doi: 10.1101/2020.09.11.293449
Contact Info: Yang Zhang: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.09.11.293449v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Fred Hutchinson Cancer Research Center
Keywords: SARS-CoV-2, Remdesivir, mathematical models, primates
Summary of Study: Developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaque
References: doi: https://doi.org/10.1101/2020.06.21.163550
Contact Info: Joshua Schiffer, [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.06.21.163550v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Fred Hutchinson Cancer Research Center
Keywords: SARS-CoV-2, Remdesivir, mathematical models, primates
Summary of Study: Developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaque
References: doi: https://doi.org/10.1101/2020.06.21.163550
Contact Info: Joshua Schiffer, [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.06.21.163550v1
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Sanofi Pasteur
Keywords: SARS-CoV-2, mRNA vaccine candidates, primates
Summary of Study: Several mRNA constructs expressing various structural conformations of S-protein were tested in cynomolgus macaques for their capacity to elicit neutralizing antibodies. The candidate MRT5500 was shown to be immunogenic by eliciting potent neutralizing antibodies in both mice and cynomolgus macaques and is position for further development in clinical studies as a vaccine for the prevention of COVID-19.
References: doi: https://doi.org/10.1101/2020.10.14.337535
Contact Info: none listed
URL: https://www.biorxiv.org/content/10.1101/2020.10.14.337535v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Sanofi Pasteur
Keywords: SARS-CoV-2, mRNA vaccine candidates, primates
Summary of Study: Several mRNA constructs expressing various structural conformations of S-protein were tested in cynomolgus macaques for their capacity to elicit neutralizing antibodies. The candidate MRT5500 was shown to be immunogenic by eliciting potent neutralizing antibodies in both mice and cynomolgus macaques and is position for further development in clinical studies as a vaccine for the prevention of COVID-19.
References: doi: https://doi.org/10.1101/2020.10.14.337535
Contact Info: none listed
URL: https://www.biorxiv.org/content/10.1101/2020.10.14.337535v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Northwestern University Feinberg School of Medicine; Tulane National Primate Research Center; New Iberia Research Center
Keywords: SARS-CoV-2, male genital tract, positron emission tomography, pathogenesis, primates
Summary of Study: Results suggest that SARS-CoV-2 rapidly and efficiently infects multiple tissues of the male genital tract (MGT) early during infection in rhesus macaques.
References: PMID: 35262081 / doi: 10.1101/2022.02.25.481974
Contact Info: Thomas J. Hope: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2022.02.25.481974v2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Northwestern University Feinberg School of Medicine; Tulane National Primate Research Center; New Iberia Research Center
Keywords: SARS-CoV-2, male genital tract, positron emission tomography, pathogenesis, primates
Summary of Study: Results suggest that SARS-CoV-2 rapidly and efficiently infects multiple tissues of the male genital tract (MGT) early during infection in rhesus macaques.
References: PMID: 35262081 / doi: 10.1101/2022.02.25.481974
Contact Info: Thomas J. Hope: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2022.02.25.481974v2
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: NIAID; University of Plymoth, UK; The Vaccine Group Ltd, Plymouth, UK
Keywords: SARS-CoV-2, Molnupiravir and Nirmatrelvir, virus replication, pathology, primates
Summary of Study: Combination of molnupiravir and nirmatrelvir inhibits SARS-CoV-2 replication and shedding more effectively than individual treatments in the rhesus macaque model.
References: doi: 10.1101/2022.09.03.506479
Contact Info: Heinz Feldman: vog.hin.diain@hnnamdlef
URL: https://www.biorxiv.org/content/10.1101/2022.09.03.506479v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: NIAID; University of Plymoth, UK; The Vaccine Group Ltd, Plymouth, UK
Keywords: SARS-CoV-2, Molnupiravir and Nirmatrelvir, virus replication, pathology, primates
Summary of Study: Combination of molnupiravir and nirmatrelvir inhibits SARS-CoV-2 replication and shedding more effectively than individual treatments in the rhesus macaque model.
References: doi: 10.1101/2022.09.03.506479
Contact Info: Heinz Feldman: vog.hin.diain@hnnamdlef
URL: https://www.biorxiv.org/content/10.1101/2022.09.03.506479v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Harvard Medical School; Walter Reed National Military Medical Center; Bioqual; University of Pittsburgh Medical Center; Henry Jackson Foundation; Ragon Institute of MGH, MIT, and Harvard
Keywords: SARS-CoV-2, live oral vaccine, gastrointestinal tract, pathology, immune response, primates
Summary of Study: Post-pyloric inoculation of live SARS-CoV-2 is weakly immunogenic and confers partial protection against respiratory SARS-CoV-2 challenge in rhesus macaques.
References: doi: 10.1128/JVI.01599-21
Contact Info: Dan Barouch: [email protected]
URL: https://journals.asm.org/doi/10.1128/JVI.01599-21?url_ver=Z39.88-2003&rfr_id=or…
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Harvard Medical School; Walter Reed National Military Medical Center; Bioqual; University of Pittsburgh Medical Center; Henry Jackson Foundation; Ragon Institute of MGH, MIT, and Harvard
Keywords: SARS-CoV-2, live oral vaccine, gastrointestinal tract, pathology, immune response, primates
Summary of Study: Post-pyloric inoculation of live SARS-CoV-2 is weakly immunogenic and confers partial protection against respiratory SARS-CoV-2 challenge in rhesus macaques.
References: doi: 10.1128/JVI.01599-21
Contact Info: Dan Barouch: [email protected]
URL: https://journals.asm.org/doi/10.1128/JVI.01599-21?url_ver=Z39.88-2003&rfr_id=or…
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: NIAID; Yerkes National Primate Research Center; Emory University School of Medicine; Bioqual; Moderna
Keywords: SARS-CoV-2, mRNA-vaccine, immune response, protection, virus reproduction, primates
Summary of Study: mRNA-1273 provided durable protection against B.1.617.2 challenge in the lower airways likely through anamnestic induction of antibody responses in the lung.
References: PMID: 34729558 / doi: 10.1101/2021.10.23.465542
Contact Info: Robert Seder: [email protected]; Daniel Douek: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.10.23.465542v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: NIAID; Yerkes National Primate Research Center; Emory University School of Medicine; Bioqual; Moderna
Keywords: SARS-CoV-2, mRNA-vaccine, immune response, protection, virus reproduction, primates
Summary of Study: mRNA-1273 provided durable protection against B.1.617.2 challenge in the lower airways likely through anamnestic induction of antibody responses in the lung.
References: PMID: 34729558 / doi: 10.1101/2021.10.23.465542
Contact Info: Robert Seder: [email protected]; Daniel Douek: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.10.23.465542v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, Pakistan
Keywords: SARS-CoV-2, therapeutics, an iodine complex, primates
Summary of Study: Renessans, an iodine complex which has proven in vitro antiretroviral activity, may result in early clearance of SARS-CoV-2.
References: doi: https://doi.org/10.1101/2020.11.17.377432
Contact Info: Tahir Yaqub: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.17.377432v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, Pakistan
Keywords: SARS-CoV-2, therapeutics, an iodine complex, primates
Summary of Study: Renessans, an iodine complex which has proven in vitro antiretroviral activity, may result in early clearance of SARS-CoV-2.
References: doi: https://doi.org/10.1101/2020.11.17.377432
Contact Info: Tahir Yaqub: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.17.377432v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: NIAID, Emory University, Duke University, Moderna, Bioqual
Keywords: SARS-CoV-2, mRNA vaccine, lipid nanoparticles, immune response, pathology, primates
Summary of Study: mRNA-1273 vaccine-induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP.
References: PMID: 33907752 / doi: 10.1101/2021.04.20.44067
Contact Info: Robert Seder: [email protected]; Barney Graham: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.04.20.440647v2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: NIAID, Emory University, Duke University, Moderna, Bioqual
Keywords: SARS-CoV-2, mRNA vaccine, lipid nanoparticles, immune response, pathology, primates
Summary of Study: mRNA-1273 vaccine-induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP.
References: PMID: 33907752 / doi: 10.1101/2021.04.20.44067
Contact Info: Robert Seder: [email protected]; Barney Graham: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.04.20.440647v2
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Maryland School of Medicine; Noravax
Keywords: SARS-CoV-2, receptor-binding domain subunit vaccine, immune response, mice and primates
Summary of Study: Positive results in non-human primates suggest the feasibility of utilizing a B.1.351 Spike directed variant vaccine as a booster after previous immunization with a vaccine directed toward the ancestral SARS-CoV-2 Spike protein.
References: doi: 10.1101/2021.06.08.447631
Contact Info: Matthew Frieman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.08.447631v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Maryland School of Medicine; Noravax
Keywords: SARS-CoV-2, receptor-binding domain subunit vaccine, immune response, mice and primates
Summary of Study: Positive results in non-human primates suggest the feasibility of utilizing a B.1.351 Spike directed variant vaccine as a booster after previous immunization with a vaccine directed toward the ancestral SARS-CoV-2 Spike protein.
References: doi: 10.1101/2021.06.08.447631
Contact Info: Matthew Frieman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.08.447631v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: COVAXX, Inc.; United Biomedical Inc., Asia; United BioPharma; United Biomedical Inc., USA; Academia Sinica; University of Texas Medical Branch; Galveston National Laboratory
Keywords: SARS-CoV-2, multitope protein-peptide vaccine, immunogenicity, protection, mice, rats, Guinea pigs, primates
Summary of Study: With a Phase 1 trial ongoing in Taiwan and additional trials planned worldwide, UB-612 is a highly promising and differentiated vaccine candidate for prevention of SARS-CoV-2 transmission and COVID-19 disease.
References: doi: 10.1101/2020.11.30.399154
Contact Info: Chang Yi Wang: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.30.399154v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: COVAXX, Inc.; United Biomedical Inc., Asia; United BioPharma; United Biomedical Inc., USA; Academia Sinica; University of Texas Medical Branch; Galveston National Laboratory
Keywords: SARS-CoV-2, multitope protein-peptide vaccine, immunogenicity, protection, mice, rats, Guinea pigs, primates
Summary of Study: With a Phase 1 trial ongoing in Taiwan and additional trials planned worldwide, UB-612 is a highly promising and differentiated vaccine candidate for prevention of SARS-CoV-2 transmission and COVID-19 disease.
References: doi: 10.1101/2020.11.30.399154
Contact Info: Chang Yi Wang: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.30.399154v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: IRSICaixa AIDS Research Institute; Barcelona Institute of Science & Technology; Yerkes National Primate Research Center, Emory University, and more
Keywords: SARS-CoV-2, antigen presenting myeloid cells, pathology, primates
Summary of Study: Although being largely resistant to SARS-CoV-2 infection, myeloid cells effectively capture and trap incoming viruses in internal compartments connected with the plasma membrane, eventually leading to viral degradation over time.
References: doi: 10.1101/2021.05.11.443572
Contact Info: Javier Martinez/Picado: [email protected]; Julia Vergara-Alert: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.05.11.443572v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: IRSICaixa AIDS Research Institute; Barcelona Institute of Science & Technology; Yerkes National Primate Research Center, Emory University, and more
Keywords: SARS-CoV-2, antigen presenting myeloid cells, pathology, primates
Summary of Study: Although being largely resistant to SARS-CoV-2 infection, myeloid cells effectively capture and trap incoming viruses in internal compartments connected with the plasma membrane, eventually leading to viral degradation over time.
References: doi: 10.1101/2021.05.11.443572
Contact Info: Javier Martinez/Picado: [email protected]; Julia Vergara-Alert: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.05.11.443572v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: african green monkeys
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Meissa Vaccines, Inc., BIOQUAL, Inc., University of Texas Medical Branch, Butler University, Vanderbilt University School of Medicine
Keywords: SARS-CoV-2, vaccine candidate, immune response, virus variants, primate
Summary of Study: One mucosal administration of MV-014-212 in African green monkeys protected against SARS-CoV-2 challenge. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase I clinical trials as a single-dose intranasal COVID-19 vaccine.
References: doi: 10.1101/2021.07.16.452733
Contact Info: Mariana Tioni: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.16.452733v2
NHP Species: african green monkeys
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Meissa Vaccines, Inc., BIOQUAL, Inc., University of Texas Medical Branch, Butler University, Vanderbilt University School of Medicine
Keywords: SARS-CoV-2, vaccine candidate, immune response, virus variants, primate
Summary of Study: One mucosal administration of MV-014-212 in African green monkeys protected against SARS-CoV-2 challenge. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase I clinical trials as a single-dose intranasal COVID-19 vaccine.
References: doi: 10.1101/2021.07.16.452733
Contact Info: Mariana Tioni: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.16.452733v2
Coronavirus Investigated: SARS-CoV-2
NHP Species: african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: Selva Therapeutics, Tulane National Primate Research Center, University of Texas Medical Branch, UC San Diego,
Keywords: SARS-CoV-2,cysteine protease inhibitors, antiviral effects, pathology, primates
Summary of Study: SLV is an orally available treatment likely to reduce the respiratory symptoms associated with clinical progression in COVID-19 patients. African green monkey studies with this drug demonstrated a reduction in lung weight and a reduction in coronavirus-mediated pathology in both prophylactic and treatment settings. A Phase I trial with SLV213 has recently been completed and a Phase II trial is planned (https://clinicaltrials.gov/ct2/show/NCT04843787).
References: doi: 10.1101/2021.07.20.453127
Contact Info: Felix Frueh: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.20.453127v1
NHP Species: african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: Selva Therapeutics, Tulane National Primate Research Center, University of Texas Medical Branch, UC San Diego,
Keywords: SARS-CoV-2,cysteine protease inhibitors, antiviral effects, pathology, primates
Summary of Study: SLV is an orally available treatment likely to reduce the respiratory symptoms associated with clinical progression in COVID-19 patients. African green monkey studies with this drug demonstrated a reduction in lung weight and a reduction in coronavirus-mediated pathology in both prophylactic and treatment settings. A Phase I trial with SLV213 has recently been completed and a Phase II trial is planned (https://clinicaltrials.gov/ct2/show/NCT04843787).
References: doi: 10.1101/2021.07.20.453127
Contact Info: Felix Frueh: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.20.453127v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Gritstone Bio., Inc.; Battelle Biomedical Research Center
Keywords: SARS-CoV-2, prime-boost vaccination, immune response, primates
Summary of Study: Data demonstrate that the Self-amplifying mRNA (SAM) vaccine platform can drive balanced T- and B-cell responses for optimal protective immunity at low doses, offering an additional attractive vaccine platform in the fight against current and emerging infectious pathogens.
References: doi:10.1101/2021.11.08.467773
Contact Info: Karin Jooss: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.11.08.467773v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Gritstone Bio., Inc.; Battelle Biomedical Research Center
Keywords: SARS-CoV-2, prime-boost vaccination, immune response, primates
Summary of Study: Data demonstrate that the Self-amplifying mRNA (SAM) vaccine platform can drive balanced T- and B-cell responses for optimal protective immunity at low doses, offering an additional attractive vaccine platform in the fight against current and emerging infectious pathogens.
References: doi:10.1101/2021.11.08.467773
Contact Info: Karin Jooss: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.11.08.467773v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Inovio Pharmaceuticals; The Wistar Institute
Keywords: SARS-CoV-2, DNA vaccine candidate, immunogenicity, boost, primates
Summary of Study: Data illustrate the durability of immunity following vaccination with synthetic DNA vaccine candidates INO-4800 or INP-4802 and additional support the use of either INO-4800 or INP-4802 in prime-boost regimens.
References: doi: 10.1101/2021.10.27.466163
Contact Info: Kate Broderick: [email protected]; David Weiner: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.10.27.466163v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Inovio Pharmaceuticals; The Wistar Institute
Keywords: SARS-CoV-2, DNA vaccine candidate, immunogenicity, boost, primates
Summary of Study: Data illustrate the durability of immunity following vaccination with synthetic DNA vaccine candidates INO-4800 or INP-4802 and additional support the use of either INO-4800 or INP-4802 in prime-boost regimens.
References: doi: 10.1101/2021.10.27.466163
Contact Info: Kate Broderick: [email protected]; David Weiner: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.10.27.466163v1
Coronavirus Investigated: SARS-CoV-2
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Oyster Point Pharma; Trudeau Institute
Keywords: SARS-CoV-2, varenicline tartrate, in vitro and in vivo studies, virus infection, primates
Summary of Study: The nAChR agonist varenicline has the potential to interact with and inhibit SARS-CoV-2 infection and replication.
References: doi: 10.1101/2021.06.29.450426
Contact Info: Jeffrey Nau: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.29.450426v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Oyster Point Pharma; Trudeau Institute
Keywords: SARS-CoV-2, varenicline tartrate, in vitro and in vivo studies, virus infection, primates
Summary of Study: The nAChR agonist varenicline has the potential to interact with and inhibit SARS-CoV-2 infection and replication.
References: doi: 10.1101/2021.06.29.450426
Contact Info: Jeffrey Nau: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.29.450426v1
Coronavirus Investigated: SARS-CoV-2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Intuitive Biosciences
Keywords: SARS-CoV-2, spike binding antibodies with neutralizing activity, immunization, primates
Summary of Study: Efficacy of vaccine candidates based on the SARS-CoV-2 spike was assessed in cynomolgus macaques by examining their ability to generate spike binding antibodies with neutralizing activity. Neutralizing activity persisted for more than 20 weeks. These data support the utility of spike subunit-based antigens as a vaccine for use in humans.
References: PMID: 33398285/doi: 10.1101/2020.12.20.422693
Contact Info: Kimberly Luke (no contact information)
URL: https://www.biorxiv.org/content/10.1101/2020.12.20.422693v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Intuitive Biosciences
Keywords: SARS-CoV-2, spike binding antibodies with neutralizing activity, immunization, primates
Summary of Study: Efficacy of vaccine candidates based on the SARS-CoV-2 spike was assessed in cynomolgus macaques by examining their ability to generate spike binding antibodies with neutralizing activity. Neutralizing activity persisted for more than 20 weeks. These data support the utility of spike subunit-based antigens as a vaccine for use in humans.
References: PMID: 33398285/doi: 10.1101/2020.12.20.422693
Contact Info: Kimberly Luke (no contact information)
URL: https://www.biorxiv.org/content/10.1101/2020.12.20.422693v1